Want to see SE:FLUI full AI Analyst Report?
Top Page
Fluicell AB
(FLUI)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr32.00
▲(220.00% Upside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial performance—persistent losses and ongoing negative operating/free cash flow—despite a debt-free balance sheet and improving TTM revenue and gross profit. Technicals add support due to a strong uptrend versus long-term averages and positive MACD, but elevated momentum readings (high stochastic) suggest the move may be stretched. Valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Revenue and Gross Profit Recovery
The strong TTM revenue rebound and positive gross profit indicate improving commercial traction. If sustained, higher sales can help Fluicell absorb fixed costs and move its single-cell research platform toward greater operating scale.
Negative Factors
Persistent Unprofitability
Fluicell has not yet converted improving sales into sustainable profits. Continued operating and net losses reduce internal funding capacity and indicate that its cost base remains too large relative to the current revenue scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Profit Recovery
The strong TTM revenue rebound and positive gross profit indicate improving commercial traction. If sustained, higher sales can help Fluicell absorb fixed costs and move its single-cell research platform toward greater operating scale.
Read all positive factors
Fluicell AB (FLUI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr43.82M
Dividend YieldN/A
Average Volume (3M)16.23K
Price to Earnings (P/E)76.5
Beta (1Y)1.14
Revenue Growth837.37%
EPS GrowthN/A
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.71
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio-59.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr68.60M
Fluicell AB Business Overview & Revenue Model
Company Description
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic ...
How the Company Makes Money
Fluicell makes money primarily by selling life-science research products and related services built around its single-cell microfluidics technology. Key revenue streams typically include: (1) Product sales of instruments/platforms (e.g., microflui...
Fluicell AB Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.87M | 6.00M | 1.86M | 3.34M | 3.25M | 2.60M |
| Gross Profit | 12.88M | -8.69M | 3.76M | 1.74M | 2.59M | 1.89M |
| EBITDA | -2.96M | -8.31M | -14.99M | -25.91M | -20.89M | -21.08M |
| Net Income | -2.35M | -8.33M | -15.51M | -26.55M | -21.49M | -21.72M |
Balance Sheet | ||||||
| Total Assets | 20.77M | 18.48M | 25.51M | 9.34M | 31.77M | 26.98M |
| Cash, Cash Equivalents and Short-Term Investments | 1.30M | 2.26M | 15.92M | 2.76M | 24.46M | 20.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 6.56M | 7.57M | 6.27M | 8.91M | 8.32M | 7.87M |
| Stockholders Equity | 14.21M | 10.90M | 19.23M | 425.00K | 23.45M | 19.11M |
Cash Flow | ||||||
| Free Cash Flow | -7.20M | -13.61M | -15.67M | -27.23M | -22.18M | -19.41M |
| Operating Cash Flow | -902.00K | -4.95M | -15.67M | -27.23M | -21.04M | -18.64M |
| Investing Cash Flow | -7.48M | -8.67M | -3.49M | 0.00 | -1.14M | -772.00K |
| Financing Cash Flow | -1.00K | 0.00 | 32.32M | 5.53M | 25.94M | 21.31M |
Fluicell AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | kr125.33M | -1.26 | -81.76% | ― | 55.24% | 70.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr43.82M | 76.49 | -45.97% | ― | 837.37% | ― | |
48 Neutral | kr139.03M | -2.74 | -80.87% | ― | -4.02% | 35.86% | |
41 Neutral | kr145.98M | -2.82 | 288.53% | ― | -38.46% | 9.02% | |
41 Neutral | kr557.51M | -7.65 | ― | ― | ― | -23.57% |
* Healthcare Sector Average
SE:FLUI
Fluicell AB
30.10
20.50
213.54%
SE:XINT
Xintela AB
0.17
-0.22
-57.25%
SE:BIOVIC.B
Biovica International AB Class B
0.45
-0.20
-30.34%
SE:NXTCL
NextCell Pharma AB
1.05
-0.13
-11.02%
SE:BIOWKS
Bio-Works Technologies AB
3.45
0.25
7.81%
SE:FLUO
FluoGuide A/S
34.10
-6.50
-16.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.